<DOC>
	<DOCNO>NCT03042767</DOCNO>
	<brief_summary>The main objective pilot study evaluate whether 12 week IMM-124E child nonalcoholic fatty liver disease ( NAFLD ) combination standard care treatment decrease inflammation liver measure alanine transaminase ( ALT ) . Specifically , investigator measure percent change ALT Week 0 Week 12 treatment compare placebo .</brief_summary>
	<brief_title>Anti-LPS Antibody Treatment Pediatric NAFLD</brief_title>
	<detailed_description>This randomize , double blind , placebo control , three month treatment trial child age 6-19 year . Participants recruit Children 's Healthcare Atlanta pediatric liver clinical practice.The purpose study evaluate three month treatment IMM-124E ( bovine colostrum enrich anti-LPS antibody ) combination standard care lifestyle advice safe lead great improvement hepatic inflammation , insulin sensitivity , blood lipid child nonalcoholic fatty liver disease ( NAFLD ) compare placebo standard care treatment . Investigators also seek define mechanism action response three month treatment IMM-124E .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Nonalcoholic fatty liver disease ( NAFLD ) diagnosis confirm liver biopsy MRI ALT ≥ 2 x ULN screening ( girls ≥ 46 , boys ≥ 54 ) Written informed parent consent child assent Willingness take IMM124E placebo powder 3 x daily 12 week At least 2 month attempt lifestyle change diagnosis Disease condition deem physician interfere absorption , digestion , mechanism intervention drug Diagnosis diabetes HbA1c &gt; 9 % Change supplement antioxidant therapy within past 90 day ( must stable dose willing continue throughout trial vitamin supplement , include SAMe , vitamin E , betaine , Milk thistle etc ) Use probiotic antibiotic past 30 day Use antiNAFLD medication ( metformin , thiazolidinediones , UDCA ) 30 day prior randomization Acute illness within past 2 week prior enrollment ( define fever &gt; 100.4ºF ) Planned pregnancy , nurse infant , confirm suspect pregnant screening time study enrollment Evidence chronic liver disease NAFLD ( Hepatitis B C , Alpha1 antitrypsin , Wilson 's disease ) Intolerance lactose dairybased product Unable blood drawn study visit Unwillingness provide and/or collect stool sample Current gastrointestinal ( GI ) bleed inflammatory bowel disease ( irritable bowel disease ( IBD ) , colitis ) Current enrollment another therapeutic clinical trial receipt investigational study drug within 6 month prior study enrollment Participants able willing comply protocol condition would impede compliance hinder completion study , opinion investigator</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>19 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>